Aminobenzisoxazoles with biaryl P4 moieties as potent, selective, and orally bioavailable factor Xa inhibitors
- 1 April 2006
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 16 (7) , 1795-1798
- https://doi.org/10.1016/j.bmcl.2006.01.010
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Factor Xa inhibitors in acute coronary syndromes: moving from mythology to realityJournal of Thrombosis and Haemostasis, 2005
- Rationale for the use of antifactor Xa in the treatment and prevention of venous and arterial thromboembolic eventsEuropean Journal of Clinical Investigation, 2005
- New anticoagulantsBlood, 2005
- Clinical and Experimental Experience with Factor Xa InhibitorsAmerican Journal of Cardiovascular Drugs, 2004
- The Dynamics of Thrombin FormationArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Nonpeptide Factor Xa Inhibitors: DPC423, a Highly Potent and Orally Bioavailable Pyrazole Antithrombotic AgentCardiovascular Drug Reviews, 2002
- Nonpeptide Factor Xa Inhibitors III: Effects of DPC423, an Orally-Active Pyrazole Antithrombotic Agent, on Arterial Thrombosis in RabbitsThe Journal of Pharmacology and Experimental Therapeutics, 2002
- Coagulation Factor Xa Inhibition: Biological Background and RationaleCurrent Topics in Medicinal Chemistry, 2001
- Discovery of 1-[3-(Aminomethyl)phenyl]-N-[3-fluoro-2‘-(methylsulfonyl)- [1,1‘-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a Highly Potent, Selective, and Orally Bioavailable Inhibitor of Blood Coagulation Factor XaJournal of Medicinal Chemistry, 2001
- Synthetic Inhibitors of Thrombin and Factor Xa: From Bench to BedsideThrombosis Research, 1999